256 related articles for article (PubMed ID: 31492749)
1. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.
Ponz-Sarvise M; Corbo V; Tiriac H; Engle DD; Frese KK; Oni TE; Hwang CI; Öhlund D; Chio IIC; Baker LA; Filippini D; Wright K; Bapiro TE; Huang P; Smith P; Yu KH; Jodrell DI; Park Y; Tuveson DA
Clin Cancer Res; 2019 Nov; 25(22):6742-6755. PubMed ID: 31492749
[TBL] [Abstract][Full Text] [Related]
2. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
3. Upstream and Downstream Co-inhibition of Mitogen-Activated Protein Kinase and PI3K/Akt/mTOR Pathways in Pancreatic Ductal Adenocarcinoma.
Wong MH; Xue A; Baxter RC; Pavlakis N; Smith RC
Neoplasia; 2016 Jul; 18(7):425-35. PubMed ID: 27435925
[TBL] [Abstract][Full Text] [Related]
4. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
5. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models.
Zhong H; Sanchez C; Spitzer D; Plambeck-Suess S; Gibbs J; Hawkins WG; Denardo D; Gao F; Pufahl RA; Lockhart AC; Xu M; Linehan D; Weber J; Wang-Gillam A
PLoS One; 2013; 8(10):e77243. PubMed ID: 24130864
[TBL] [Abstract][Full Text] [Related]
7. Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer.
Toren P; Kim S; Johnson F; Zoubeidi A
PLoS One; 2016; 11(4):e0152861. PubMed ID: 27046225
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Yokoi K; Fidler IJ
Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
[TBL] [Abstract][Full Text] [Related]
9. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
11. KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling.
Appleman VA; Ahronian LG; Cai J; Klimstra DS; Lewis BC
Mol Cancer Res; 2012 Sep; 10(9):1228-39. PubMed ID: 22871572
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
Dumble M; Crouthamel MC; Zhang SY; Schaber M; Levy D; Robell K; Liu Q; Figueroa DJ; Minthorn EA; Seefeld MA; Rouse MB; Rabindran SK; Heerding DA; Kumar R
PLoS One; 2014; 9(6):e100880. PubMed ID: 24978597
[TBL] [Abstract][Full Text] [Related]
13. ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib.
Frolov A; Schuller K; Tzeng CW; Cannon EE; Ku BC; Howard JH; Vickers SM; Heslin MJ; Buchsbaum DJ; Arnoletti JP
Cancer Biol Ther; 2007 Apr; 6(4):548-54. PubMed ID: 17457047
[TBL] [Abstract][Full Text] [Related]
14. ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.
Liles JS; Arnoletti JP; Tzeng CW; Howard JH; Kossenkov AV; Kulesza P; Heslin MJ; Frolov A
Cancer Biol Ther; 2010 Sep; 10(6):555-63. PubMed ID: 20647770
[TBL] [Abstract][Full Text] [Related]
15. Amiloride sensitizes human pancreatic cancer cells to erlotinib in vitro through inhibition of the PI3K/AKT signaling pathway.
Zheng YT; Yang HY; Li T; Zhao B; Shao TF; Xiang XQ; Cai WM
Acta Pharmacol Sin; 2015 May; 36(5):614-26. PubMed ID: 25864651
[TBL] [Abstract][Full Text] [Related]
16. Scaffolding Protein Connector Enhancer of Kinase Suppressor of Ras 1 (CNKSR1) Regulates MAPK Inhibition Responsiveness in Pancreas Cancer via Crosstalk with AKT Signaling.
Li D; Miermont AM; Sable R; Quadri HS; Mathews Griner LA; Martin SE; Odzorig T; De S; Ferrer M; Powers AS; Hewitt SM; Rudloff U
Mol Cancer Res; 2023 Apr; 21(4):316-331. PubMed ID: 36790955
[TBL] [Abstract][Full Text] [Related]
17. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.
Williams TM; Flecha AR; Keller P; Ram A; Karnak D; Galbán S; Galbán CJ; Ross BD; Lawrence TS; Rehemtulla A; Sebolt-Leopold J
Mol Cancer Ther; 2012 May; 11(5):1193-202. PubMed ID: 22411900
[TBL] [Abstract][Full Text] [Related]
19. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
20. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
